Deadenylases are best known for degrading the poly(A) tail during mRNA decay. The deadenylase family has expanded throughout evolution and, in mammals, consists of 12 Mg 2+ -dependent 3′-end RNases with substrate specificity that is mostly unknown 1 . Pontocerebellar hypoplasia type 7 (PCH7) is a unique recessive syndrome characterized by neurodegeneration and ambiguous genitalia 2 . We studied 12 human families with PCH7, uncovering biallelic, loss-of-function mutations in TOE1, which encodes an unconventional deadenylase 3,4 . toe1-morphant zebrafish displayed midbrain and hindbrain degeneration, modeling PCH-like structural defects in vivo. Surprisingly, we found that TOE1 associated with small nuclear RNAs (snRNAs) incompletely processed spliceosomal. These pre-snRNAs contained 3′ genome-encoded tails often followed by posttranscriptionally added adenosines. Human cells with reduced levels of TOE1 accumulated 3′-end-extended pre-snRNAs, and the immunoisolated TOE1 complex was sufficient for 3′-end maturation of snRNAs. Our findings identify the cause of a neurodegenerative syndrome linked to snRNA maturation and uncover a key factor involved in the processing of snRNA 3′ ends.
characterized by neurological deterioration, atrophy or hypoplasia of the pons and cerebellum, muscular hypotonia and breathing abnormalities, in combination with hypogonadism 2 . This combination of rare conditions suggests a unique syndromic association due to mutation of a single gene, but no locus or causative gene has been identified to date. We recruited 12 families meeting criteria for PCH7, including the index family on the basis of which the condition was defined (Fig. 1a) , and we confirmed that the clinical features of these families matched those published for PCH7 (Supplementary Table 1 ). These features included reduced pons and cerebellum parenchyma (Fig. 1b) , ventriculomegaly, thin corpus callosum and variable hypogonadism-ranging from absent gonads to ovarian and uterine remnants or atrophic and undescended testes ( Supplementary  Fig. 1a,b) . All patients and families were enrolled in institutional review board (IRB)-approved protocols at referral institutions and provided consent for study. We performed whole-exome sequencing in the proband and parents from Egyptian families 1275 and 1603. Aligning the genomic variants uncovered a homozygous mutation in TOE1 encoding p.Glu220Lys (NC_000001.11) within a shared haplotype of 500 kb ( Fig. 2a and Supplementary Fig. 2a,b) , which is indicative of shared ancestry for these families. All ten additional families enrolled subsequently proved positive for biallelic mutations in TOE1 ( Fig. 2a and Supplementary Table 2) . The variants were all predicted to impair expression of full-length TOE1 or affect protein function 6 by altering well-conserved amino acids (Fig. 2b) and were not observed Biallelic mutations in the 3′ exonuclease TOE1 cause pontocerebellar hypoplasia and uncover a role in snRNA processing l e t t e r s in our in-house database of 4,000 ancestry-matched exomes. We confirmed that each variant segregated according to a recessive mode of inheritance in all genetically informative members of each family, suggesting that TOE1 biallelic mutations underlie PCH7.
To test whether TOE1 missense mutations were likely to interfere with protein function, we modeled them on the structure of the protein encoded by paralogous CNOT7 (UniProt, Q9UIV1) ( Supplementary Fig. 3a) . Most variant residues were on the surface rather than within the RNA-binding cleft, suggesting that they are not likely to directly affect deadenylase activity (Fig. 2c) l e t t e r s p.Ala103Thr, as well as their unaffected relatives (families 1603, 4127 and 4128, respectively). Patient-derived fibroblasts had reduced levels of TOE1 protein as determined by protein blot (Fig. 2d and Supplementary Fig. 3b ). Additionally, neural progenitor cell (NPC) lines that were derived from an affected individual of family 1603 showed less TOE1 protein than NPC lines from an unaffected relative and control NPCs ( Fig. 2e and Supplementary Fig. 3b,c) . Together, these results indicate that TOE1 amino acid substitutions negatively affect protein accumulation. To assess whether TOE1 mutations affect protein levels, we generated single-site-integration T-REx-293 cell lines for tetracycline-regulated expression of small interfering RNA (siRNA)-resistant transcripts for wild-type human TOE1 and the Glu220Lys, Phe148Tyr, Val173Gly and Ala103Thr variants. When cells were depleted of endogenous TOE1 and induced with a concentration of tetracycline that promoted accumulation of wild-type TOE1 to near-endogenous levels, we observed reduced levels of mutant TOE1 as compared with wild-type TOE1, despite similar mRNA levels ( Supplementary Fig. 3d,e) . In contrast, a previously characterized, catalytically inactive mutant of TOE1 (DE) accumulated to similar levels as wild-type protein (Supplementary Fig. 3e ) 4 . These results are consistent with our findings from patient-derived cell lines and indicate that the mutations in affected individuals are deleterious by reducing TOE1 levels.
Because human TOE1 and mouse Toe1 were expressed in all tested tissues ( Supplementary Fig. 4a,b) , we generated Toe1-mutant mice to test for defects in vivo. Embryos with homozygous Toe1 frameshift mutations showed uniform lethality before embryonic day (E) 11.5 ( Supplementary Fig. 4c ), demonstrating that Toe1 is required for mouse development. Because the mutations in human patients allow for partial expression of TOE1 protein, we next turned to morpholino (MO)-based knockdown in zebrafish, where protein dosage could be regulated, to create a PCH7 disease model (Supplementary Fig. 5a) l e t t e r s curly tail in 90% of embryos by 48 hours post-fertilization (h.p.f.), which was rescued by co-injection with human TOE1 mRNA but not mRNA encoding the catalytically inactive DE mutant or the mutants identified in patients ( Fig. 3a and Supplementary Fig. 6a ). To visualize neurons, we performed whole-mount immunofluorescence for the neuronal marker HuC. Like the human patients, zebrafish injected with toe1 MO showed structural defects of the developing midbrain, cerebellum and hindbrain (Fig. 3b) . This phenotype was largely rescued by co-injection with wild-type zebrafish toe1 or human TOE1, but not the mutant mRNAs ( Fig. 3b and Supplementary Figs . 5b and 6b). To determine whether neuronal loss in the zebrafish injected with toe1 MO was due to cell death, we performed staining for cleaved caspase-3 (Casp3) at 24 h.p.f. While zebrafish injected with control MO showed few Casp3-positive cells, those injected with toe1 MO showed a dramatic apoptotic response that was consistent with neurodegeneration ( Supplementary Fig. 5c ). We conclude that reduced expression of TOE1 leads to neurodegeneration and PCH-like structural brain defects in vivo.
TOE1 was originally identified as a growth suppressor and a direct target gene of ERG1, an immediate-early transcription factor 3 . We reported TOE1, which is alternatively called CAF1z because of homology with CAF1 deadenylases, as a 3′-to-5′ exonuclease with a preference for adenosines in vitro 4 . Unlike characterized mRNA deadenylases, TOE1 is concentrated in nuclear Cajal bodies 4 . Cajal bodies l e t t e r s are rich in enzymes that process RNAs not known to have poly(A) tails, suggesting that TOE1 might target non-poly(A) RNA substrates. More recently, TOE1 was shown to associate with spliceosomal proteins 7, 8 , which are known to localize to Cajal bodies, and TOE1 depletion caused defective splicing of a pre-mRNA reporter 7 . To validate TOE1 association with the spliceosome, we performed TOE1 knockdown together with expression at near-endogenous levels of FLAG-tagged wild-type or DE mutant TOE1 in T-REx-293 cells followed by immunoprecipitation (IP). As assessed by RNA blotting (Fig. 4a) and tandem mass spectrometry (MS) ( Supplementary  Fig. 7 and Supplementary Table 3 ), TOE1 assembled with snRNAs and, in near-complete overlap with previously reported immunoprecipitation and mass spectrometry (IP-MS) results 7 , with spliceosomal proteins. The CCR4-like protein ANGEL2 (also known as CCR4D), which we previously reported in complex with TOE1 (ref. 4) , was not detected in our IP-MS analysis, possibly owing to low cellular abundance of this protein 9 . Inspection of RNA blots for snRNAs associated with the DE TOE1 catalytic mutant revealed slower-migrating U1, U2 and U5 snRNA species (Fig. 4a) . Processing of RNA polymerase II (Pol II)-transcribed snRNAs (U1, U2, U4 and U5) initiates with co-transcriptional cleavage by the Integrator complex downstream of the mature 3′ end 10 , but the mechanism mediating the removal of the 3′ tail to produce a mature-length snRNA is unknown 11, 12 . To characterize the snRNAs that migrated slower in the RNA blots, we performed 3′-end sequencing of TOE1-associated snRNAs and found that TOE1 bound to Pol II-transcribed snRNAs that were incompletely processed at the 3′ end (Fig. 4b,c and Supplementary Fig. 8 ), suggesting that TOE1 may mediate snRNA 3′-tail processing.
The 3′-tail sequences of TOE1-associated pre-snRNAs consisted of both genome-encoded and post-transcriptionally added nucleotides, henceforth referred to as templated and untemplated tails, respectively (Fig. 4b,c and Supplementary Fig. 9a ). The untemplated snRNA tails, which were previously observed by global 3′-end sequencing of noncoding RNA 13 , were found almost exclusively on snRNAs that were either longer or shorter than their annotated mature length and consisted primarily of uridines and adenosines, with snRNAs associated with DE TOE1 predominantly enriched for untemplated 3′ adenosines ( Supplementary Fig. 9a,b) . Interestingly, 3′ maturation of U2 snRNA finishes with the addition of an untemplated 3′ adenosine 14 , but this modification was entirely absent from TOE1-associated U2 snRNAs (Supplementary Fig. 9b ). Taken together, these observations suggest that TOE1 associates specifically with pre-snRNAs that are not fully processed at the 3′ end and have often acquired untemplated tails.
snRNAs associated with DE TOE1 contained longer tails than those associated with wild-type TOE1, suggesting that TOE1 may catalytically process these tails. In accordance with this hypothesis, 3′-end sequencing of the total snRNA pool showed an increased fraction of 3′-end-extended snRNAs upon depletion of TOE1 ( Fig. 4b and  Supplementary Fig. 8) . Notably, complementation with exogenous wild-type TOE1 rescued the snRNA 3′-end defect, while addition of DE TOE1 failed to rescue the defect ( Fig. 4b and Supplementary Fig. 8 ).
There was little to no accumulation of 3′ tails for C/D-box U3 and H/ACA-box SNORA63 small nucleolar RNAs (snoRNAs), 5.8S rRNA, tRNAs and U6 snRNA (Supplementary Figs. 8 and 10) , which, like Pol II-transcribed snRNAs, are processed from 3′-extended precursor RNAs [15] [16] [17] [18] . These results support a catalytic role for TOE1 as a 3′-to-5′ exonuclease with specificity for snRNA processing.
TOE1 could promote either maturation or degradation of presnRNAs. To distinguish between these possibilities, we tested the activity of immunoisolated TOE1 on co-purifying pre-snRNA l e t t e r s ribonucleoprotein complexes (pre-snRNPs) in vitro. RNA blot analyses showed Mg 2+ -and active-site-dependent shortening of U1, U2 and U5 pre-snRNAs by TOE1 with no overall loss of snRNA levels (Fig. 5a) , suggesting that TOE1 has a function in maturation rather than degradation. 3′-end sequencing confirmed that the in vitro processing of U1, U2 and U5 by TOE1 halted at or before the mature 3′ end ( Fig. 5b and Supplementary Fig. 11a ), including at an alternative U5 3′ end also present in total cellular snRNA (Supplementary Fig. 8b ). In accordance with TOE1 having a function in maturation rather than degradation, TOE1 depletion did not affect the levels of unstable endogenous variants of U1 snRNA (Supplementary Fig. 11b ) 19 , nor did it affect the levels or 3′ processing of unstable U1 snRNAs mutated in the Sm-binding site ( Supplementary Fig. 11c,d ) 20 , suggesting that the latter are targeted for degradation before 3′ processing by TOE1. We conclude that TOE1 acts in snRNA 3′-end maturation (Fig. 5c) .
To determine whether TOE1 mutations affect snRNA processing in the individuals in whom they are present, we performed snRNA 3′-end sequencing in the patient-derived cell lines. This identified an increased fraction of U1 and U2 snRNAs, as well as U5 snRNA to a lesser extent, that contained tails in fibroblasts derived from patients with TOE1 mutations when compared to those derived from their unaffected relatives, which were indistinguishable from the control (Fig. 6a and Supplementary Fig. 12a,b) . Similarly, patient-derived NPC lines showed enrichment for snRNA extensions (Fig. 6b and  Supplementary Fig. 12a,b) . We conclude that cells derived from patients with PCH7 accumulate incompletely processed snRNAs.
In summary, we have shown that individuals with PCH7 harbor biallelic, damaging mutations in TOE1 that result in the accumulation of incompletely processed snRNAs. The involvement of TOE1 in snRNA maturation was surprising, given the homology of TOE1 with CAF1 mRNA deadenylases and its preference for poly(A) RNA in vitro 4 . However, this result could provide a mechanistic explanation for the observed defect in pre-mRNA splicing upon TOE1 depletion 7 . The enrichment of snRNAs with untemplated 3′ adenosines associated with catalytically inactive TOE1 suggests that 3′ adenylation by an unknown 3′-terminal nucleotidyltransferase (3′ TnT) serves as a mechanism to recruit TOE1 to pre-snRNAs (Fig. 5c) . The abundance of Sm subunits in the TOE1 IP-MS analysis ( Supplementary Fig. 7 and Supplementary  Table 3 ) and the absence of processing of U1 snRNA mutated in the Smbinding site (Supplementary Fig. 11d ) suggest that the Sm complex is another component important for TOE1 recruitment. PARN, which has been linked to familial pulmonary fibrosis, and PARN-like DEDD deadenylases were recently found to promote 3′ processing of snoRNAs and PIWI-interacting RNAs (piRNAs), respectively 15, 21, 22 , and, like snRNAs, RNA targets had templated and untemplated tails upon depletion of PARN 15 . Thus, the adaptation of deadenylases to function in 3′ processing of noncoding RNAs in conjunction with poly(A) polymerases might be a general principle in RNA metabolism.
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Our results suggest that perturbations in snRNA pools may contribute to the features manifested by patients with PCH7, although other currently unknown functions of TOE1 cannot be ruled out as being causal in the disease. A defining feature of pontocerebellar degeneration is loss of motor neurons, akin to spinal muscular atrophy (SMA). The gene associated with SMA, SMN1 (survival of motor neuron 1), encodes a well-established snRNP assembly factor 23, 24 , and this association, together with our results, suggests that maintaining proper snRNP biogenesis is important for neuronal survival. EXOSC3, which encodes a core component of the 3′-RNA-exonuclease exosome complex, is mutated in PCH type 1 (ref. 25) , suggesting that there may be shared RNA targets for TOE1 and the exosome, perhaps snRNAs. In accordance with the idea that snRNAs are important for neuronal survival, a recent study identified recessive cerebellar degeneration resulting from a mutation in the Rnu2-8 U2 snRNA gene in mice 26 . We and others recently described mutations in genes involved in protein synthesis, including CLP1 and other tRNA splicing endonuclease (TSEN) complex components, leading to misprocessing of pre-tRNAs in cells derived from patients with PCH [27] [28] [29] [30] . While we found no defect in tRNA 3′-end processing in TOE1-mutant cells (Supplementary Fig. 10 ), CLP1 has also been implicated in snRNA 3′-end processing 31 , suggesting a possible link between TOE1 and CLP1 mutations in PCH. Our data, along with data from other recent studies 26, 32 , suggest defects in the processing of small noncoding RNAs as a common cause of severe, early-onset neurodegenerative conditions. 
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METHODS
Patient recruitment. Patients were enrolled and sampled according to standard local practice in approved human subjects protocols at the University of California, The Rockefeller University and The Academic Medical Center (AMC) in Amsterdam for blood, saliva and skin biopsy sampling.
Sequencing. Blood was acquired from informed, consenting individuals according to institutional guidelines, and DNA was extracted using established protocols. Exome sequencing was performed on both the parents and affected member(s) from each family as previously described 34 . All variants were prioritized by allele frequency, conservation and predicted effect on protein function, and were tested by Sanger sequencing for segregation with disease. Sequence data were analyzed with Sequencer 4.9 (Gene Codes).
Genetic mapping. Chromosomal ideogram plots were generated using the Bioconductor package quantsmooth. Red represents homozygous regions that segregate between affected and unaffected family members.
Fibroblast culture, and iPSC and NPC generation. Fibroblasts were generated from unaffected and affected dermal biopsy explants. Induced pluripotent stem cells (iPSCs) and NPCs were obtained as previously described 35 . Mycoplasma testing was routinely performed, and all cell lines were negative.
cDNA synthesis and RT-PCR. cDNA was synthesized with the Superscript III First-Strand cDNA synthesis system for RT-PCR (Life Technologies) and used for real-time PCR or cloning. qRT-PCR for intron-containing tRNAs was performed in triplicate on 10 ng of human cDNA 27 . RT-PCR to assess toe1 intron inclusion in zebrafish embryos morphant for toe1 splice-blocking MO was performed with 10 ng of zebrafish cDNA and primers flanking the first intron of zebrafish toe1 (Supplementary Table 4) .
Plasmid constructs and stable cell line generation. The ORF of human TOE1 was subcloned into pcDNA5/FRT/TO-FLAG with BamHI and NotI restriction sites from pcDNA3-FLAG 4 . The ORF of zebrafish toe1 or human TOE1 was subcloned into pCS2+ (ref. 36 ) with BamHI and XhoI. Missense mutations were generated using the QuikChange Mutagenesis kit (Agilent). For expression of N-terminally FLAG-tagged proteins, stable HEK FLp-In T-REx-293 cell lines were generated (Invitrogen). Mycoplasma testing was routinely performed, and all cell lines were negative. RNA blotting. RNA was extracted using TRIzol and separated by electrophoresis on 9% 19:1 polyacrylamide, 0.6× Tris/borate/EDTA (TBE), 8 M urea gels at 20 mA per gel for 2 h. RNA was transferred in 0.5× TBE to nylon membrane at 25 V for 16 h. Membranes were UV cross-linked, blocked with Ultrahyb Oligo (Life Technologies) and hybridized with 5′-end-radiolabeled DNA oligonucleotides (Supplementary Table 4) . 3′ RNA tail sequencing and analysis. RNA adaptors containing barcodes and 10-to 11-nt randomers (Supplementary Table 4) were ligated to the 3′ ends of total and eluted RNA with T4 RNA ligase (New England BioLabs) at 16 °C for 16 h, treated with RQ1 RNase-free DNase (Promega) for 30 min at 37 °C and extracted with PCA (Affymetrix). cDNA was generated using AR-17 primer with Superscript III (Life Technologies). 3′ ends were amplified by Q5 DNA polymerase (New England BioLabs) with snRNA-gene-specific primers and AR-17, and then with primers D501 and D702 (Illumina; Supplementary Table 5 ). For tRNA 3′-end sequencing, tRNAs were gel purified from a 9% polyacrylamide urea gel and libraries were prepared using the eCLIP input RNA protocol (days 3 and 4) 37 with the AG10N and AG11N 3′ RNA adaptors and the 3Tr3 5′ DNA adaptor (Supplementary Table 5 ). All libraries were purified on AMPure XP magnetic beads (Beckman) and validated by 2200 TapeStation (Agilent). Libraries were pooled at a 4 nM concentration, denatured with NaOH and diluted in HT1 buffer (Illumina) to 7 pM and were then sequenced with MiSeq Reagent Kit V2, Nano configuration (Illumina). snRNA 3′ sequence reads were decomplexed, and duplicates were removed based on randomer sequences. Sequences were aligned with snRNA genes (including downstream regions) from Ensembl. snRNA 3′-end positions were identified based on perfect alignment with one or more snRNA genes (reads with nucleotide mismatches were removed from the analyses), and 3′ untemplated tails were identified as 3′ sequence additions that did not align with the genomic sequence. Each experiment generally generated 5,000-35,000 unique mapped reads, with the lowest number being 1,173 (Supplementary Table 4) . Cumulative plots were generated from reads mapping to all U1, U4, U5 and U6 variants, whereas for U2 separate cumulative plots were generated for reads mapping to the RNU2-1 and RNU2-2P genes and reads were trimmed for the A and CA tails that are post-transcriptionally added to mature RNU2-1 and RNU2-2P RNAs, respectively, to allow discrimination of the mature U2 snRNAs from those that are incompletely 3′-end exonucleolytically processed (Figs. 4 and 6, and Supplementary Figs. 8b and 11a) .
RNA immunoprecipitation and TOE1 activity assays. One 10-cm dish of stable cell lines expressing siRNA-resistant FLAG-TOE1 variants was transfected twice with 20 nM siRNA (Dharmacon) targeting either luciferase (siCtrl) or the 3′ UTR of TOE1 (siTOE1) using siLentFect (Bio-Rad) 72 h and 24 h before cell collection. Treatment with siTOE1 generally resulted in ~10-20% remaining protein, as determined by protein blot (Supplementary Fig. 3d) . At ~50% density, cells were induced for 24 h with tetracycline (1 ng/ml), collected in PBS and lysed in isotonic buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.2 mM EDTA, 0.1% Triton X-100, 1 mM PMSF, 2 µg/ml aprotinin, 2 µg/ml leupeptin, 0.1 µg/ml yeast total RNA (Roche) and 80 U/ml RNaseOUT (Invitrogen) for 10 min on ice. Lysates were cleared at 20,000g for 15 min at 4 °C. FLAG peptide was added to 1 µg/ml, and lysates were incubated for 2 h with anti-FLAG M2 beads (Sigma) at 4 °C. Beads were washed eight times with NET2 (10 mM Tris, pH 7.5, 150 mM NaCl and 0.1% Triton X-100). One-fifth of the beads were eluted in protein loading buffer, and the rest were resuspended in TRIzol (Life Technologies). RNA was extracted according to the manufacturer's protocol. Activity assays were performed after washing and on the beads for 30 min at 25 °C with either 2 mM EDTA or 2 mM MgCl 2 .
Protein blotting. Protein blotting was performed with rabbit polyclonal antibody to Caf1z/Toe1 (ref. 4) , rabbit polyclonal antibody to GAPDH (Cell Signaling, 2118s) and mouse antibody to vinculin (Sigma, V9264) at 1:1,000 dilutions in 5% nonfat milk in PBST. The secondary antibodies were HRPconjugated anti-mouse and anti-rabbit secondary antibodies used at 1:20,000 dilutions in 5% nonfat milk in PBST.
Animals.
All animal experiments complied with the Institutional Animal Care and Use Committee at the University of California San Diego and were carried out in a non-blinded fashion. The Toe1-mutant mice were generated using CRISPR/ SpCas9 technology. Briefly, pronuclear co-injection with 5 ng of Cas9 mRNA and 2.5 ng of sgRNA (targeting sequence, 5′-CTGTGTGAGATGTTCCCAGC-3′) was performed on 143 embryos. A total of 126 embryos were transferred into host dams for implantation, resulting in 23 live pups. Sanger sequence genotyping identified only one mouse with a heterozygous single-base-pair frameshift mutation (chr. 4: 116806688-89insA; c.668_669insA), resulting in a Toe1 null allele. Mutagenesis was performed on C57BL/6J single-cell blastocysts. Positive founders were bred to establish lines transmitting the Toe1 null allele. Male and female carriers were intercrossed at 6-8 weeks of age to assess the embryonic phenotype associated with Toe1 mutation.
Adult male and female zebrafish (<18 months old) from wild-type (AB Tubingen) and transgenic strains were maintained under standard laboratory conditions. At least three adult pairs were used to generate embryos at 0-48 h.p.f. for each experiment. Translation-blocking antisense MO (7 ng), splice-blocking antisense MO (6 ng) and control non-targeting MO (7 ng) (Supplementary Table 5 ) (Gene Tools) were injected into one-cell-stage embryos. Gross morphology of zebrafish was assessed at 48 h.p.f., and embryos were defined as affected if they had an obviously misshapen head, small eyes and a curly tail (>10% reduction in head/eye size and >10° change in the angle of the tail). HuC/HuD whole-mount immunostaining was used to assess the presence of neuronal tissue. For mRNA rescue experiments, 0.1 pg of in vitro-transcribed zebrafish toe1 or human TOE1 mRNA (mMESSAGE mMACHINE, Ambion) was co-injected with 6 ng of splice-blocking MO into one-cell-stage embryos, and embryos were assessed at 48 h.p.f. for morphological differences and neuronal tissue (minimum of 100 embryos per condition). Immunofluorescent staining was performed as previously described 38 with
